BidaskClub lowered shares of Fluidigm (NASDAQ:FLDM) from a buy rating to a hold rating in a report published on Tuesday, BidAskClub reports.

Other research analysts also recently issued research reports about the stock. BTIG Research started coverage on shares of Fluidigm in a report on Wednesday, March 13th. They issued a buy rating and a $15.00 price target for the company. Zacks Investment Research raised shares of Fluidigm from a strong sell rating to a buy rating and set a $13.00 price target for the company in a report on Tuesday, March 5th. ValuEngine raised shares of Fluidigm from a hold rating to a buy rating in a report on Thursday, June 6th. UBS Group started coverage on shares of Fluidigm in a report on Friday, March 15th. They issued a neutral rating and a $14.00 price target for the company. Finally, Piper Jaffray Companies increased their price target on shares of Fluidigm from $14.00 to $16.00 and gave the company an overweight rating in a report on Friday, May 3rd. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $14.50.

Shares of NASDAQ:FLDM opened at $11.87 on Tuesday. The company has a quick ratio of 2.86, a current ratio of 3.26 and a debt-to-equity ratio of 0.30. Fluidigm has a 12 month low of $4.65 and a 12 month high of $14.90. The stock has a market capitalization of $819.27 million, a P/E ratio of -14.84 and a beta of 2.32.

Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.30). Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The business had revenue of $30.10 million during the quarter, compared to the consensus estimate of $29.18 million. The firm’s revenue for the quarter was up 19.4% on a year-over-year basis. On average, sell-side analysts forecast that Fluidigm will post -0.5 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. bought a new position in shares of Fluidigm during the first quarter valued at approximately $159,000. MetLife Investment Advisors LLC bought a new position in shares of Fluidigm during the first quarter valued at approximately $214,000. Metropolitan Life Insurance Co NY bought a new position in shares of Fluidigm during the first quarter valued at approximately $151,000. FMR LLC bought a new position in shares of Fluidigm during the first quarter valued at approximately $24,188,000. Finally, Perceptive Advisors LLC bought a new position in shares of Fluidigm during the first quarter valued at approximately $612,000. 92.64% of the stock is currently owned by institutional investors.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Further Reading: What is the Current Ratio?

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.